Outcomes of Single-Agent Onasemnogene Abeparvovec or Nusinersen, and of Nusinersen Switching to Onasemnogene Abeparvovec, in Patients With Spinal Muscular Atrophy: Results of a Provider Survey in the United States (2346)

Yang, Min; Georgieva, Mihaela; Q. Wu, Eric; Dabbous, Omar; LaMarca, Nicole; Shenouda, Lydia; Patel, Anish; Toro Jimenez, Walter; Bischof, Matthias; B. Minkoff, Neil

doi:10.1212/wnl.96.15_supplement.2346

Public

Outcomes of Single-Agent Onasemnogene Abeparvovec or Nusinersen, and of Nusinersen Switching to Onasemnogene Abeparvovec, in Patients With Spinal Muscular Atrophy: Results of a Provider Survey in the United States (2346)

Published in Neurology • Apr 13, 2021

Authors:

Min Yang

Mihaela Georgieva

Eric Q. Wu

Abstract

To understand providers’ assessment of outcomes following disease-modifying therapy (DMT; onasemnogene abeparvovec or nusinersen monotherapy, or onasemnogene abeparvovec following nusinersen) in patients with spinal muscular atrophy (SMA).

Subject

Spinal muscular atrophy

Medicine

Atrophy

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!